Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Ointments: SOP for Handling Deviations in Ointment Manufacturing – V 2.0

Posted on By

SOP for Handling Deviations in Ointment Manufacturing – V 2.0

Procedure for Handling Deviations in Ointment Manufacturing

Department Production/Quality Assurance (QA)/Quality Control (QC)
SOP No. DM-030
Supersedes V 1.0
Page No. Page X of Y
Issue Date [Insert Issue Date]
Effective Date [Insert Effective Date]
Review Date [Insert Review Date]

1. Purpose

The purpose of this Standard Operating Procedure (SOP) is to define a structured approach for identifying, documenting, investigating, and resolving deviations in ointment manufacturing. Proper deviation management ensures compliance with GMP standards and prevents potential product quality issues.

2. Scope

This SOP applies to all personnel involved in the ointment manufacturing process, including production, quality control (QC), and quality assurance (QA) teams.

3. Responsibilities

  • Production Supervisor: Identifies and reports deviations in the manufacturing process.
  • QA Personnel: Reviews deviations, initiates investigations, and recommends corrective actions.
  • QC Analyst: Conducts testing and verification of affected products.
  • Engineering Team: Assists in investigating equipment-related deviations.
See also  Ointments: SOP for Handling Interruptions During Ointment Manufacturing - V 2.0

4. Accountability

The QA Manager is accountable for ensuring that all deviations are recorded, investigated, and resolved as per GMP standards.

5. Procedure

5.1 Types of Deviations

  • Minor Deviation: A deviation that does not affect product quality or GMP compliance.
  • Major Deviation: A deviation that impacts product quality, safety, or compliance.
  • Critical Deviation: A serious deviation that leads to product rejection or regulatory non-compliance.

5.2 Identification and Reporting

  • Any personnel detecting a deviation must report it immediately to the Production Supervisor.
  • The
deviation must be documented in the Deviation Log with details such as batch number, description, and date.
  • The QA team must classify the deviation based on severity.
  • 5.3 Investigation of Deviations

    • QA will assign an investigation team to analyze the deviation.
    • Root cause analysis (RCA) must be conducted using tools such as:
      • 5-Why Analysis
      • Fishbone Diagram
      • Failure Mode and Effects Analysis (FMEA)
    • Determine whether the deviation affects product quality or safety.
    • Document investigation findings in the Deviation Investigation Report.

    5.4 Corrective and Preventive Actions (CAPA)

    • Corrective Action: Immediate measures to correct the deviation.
    • Preventive Action: Long-term measures to prevent recurrence.
    • QA must approve CAPA plans before implementation.

    5.5 Documentation and Approval

    • Record all deviation details in the Deviation Log.
    • QA must approve all deviations before batch release.
    • For critical deviations, a detailed report must be submitted to regulatory authorities if required.

    6. Abbreviations

    • GMP – Good Manufacturing Practices
    • QA – Quality Assurance
    • QC – Quality Control
    • RCA – Root Cause Analysis
    • CAPA – Corrective and Preventive Actions

    7. Documents

    • Deviation Log (Annexure-1)
    • Deviation Investigation Report (Annexure-2)
    • CAPA Report (Annexure-3)

    8. References

    • WHO GMP Guidelines for Pharmaceutical Manufacturing
    • 21 CFR Part 211 – Current Good Manufacturing Practices
    • ICH Q10 Pharmaceutical Quality System

    9. SOP Version

    Version 2.0

    10. Approval Section

    Prepared By Checked By Approved By
    Signature
    Date
    Name
    Designation
    Department

    11. Annexures

    Annexure-1: Deviation Log

    Date Batch Number Deviation Type Description Reported By Verified By
    01/02/2025 DM-001 Minor Mixing time exceeded by 2 minutes John Doe QA Officer
    02/02/2025 DM-002 Major Temperature fluctuation during cooling Jane Smith QA Officer

    Annexure-2: Deviation Investigation Report

    Date Batch Number Root Cause Impact on Quality Investigation By Final Decision
    01/02/2025 DM-001 Operator error No impact QA Team Approved
    02/02/2025 DM-002 Equipment malfunction Requires reprocessing QA Team Rework

    Annexure-3: CAPA Report

    Date Batch Number Corrective Action Preventive Action Implemented By Verified By
    01/02/2025 DM-001 Retraining of staff Revised SOP Production Team QA Officer
    02/02/2025 DM-002 Repaired cooling system Periodic maintenance schedule Engineering QA Officer

    12. Revision History:

    Revision Date Revision No. Details of Revision Reason for Revision Approved By
    01/01/2024 1.0 Initial Version New SOP QA Head
    01/02/2025 2.0 Updated SOP Format Standardization of Document QA Head
    See also  Ointments: SOP for Documentation of Formulation Development Process - V 2.0
    Ointments V 2.0 Tags:Ointment application SOP, Ointment batch record SOP, Ointment compounding SOP, Ointment dispensing SOP, Ointment filling SOP, Ointment formulation SOP, Ointment manufacturing SOP, Ointment microbiological testing SOP, Ointment pH testing SOP, Ointment production SOP, Ointment quality control SOP, Ointment stability study SOP, Pharmaceutical ointment SOP, SOP for ointment homogenization, SOP for ointment labeling, SOP for ointment mixing, SOP for ointment packaging, SOP for ointment preparation, SOP for ointment raw material testing, SOP for ointment shelf-life determination, SOP for ointment stability testing, SOP for ointment sterilization, SOP for ointment storage, SOP for ointment testing, SOP for ointment viscosity testing

    Post navigation

    Previous Post: Tablets: SOP for Continuous Tablet Manufacturing Process – V 2.0
    Next Post: SOP for Preparing and Maintaining EHS Policies

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

    English
     - 
    en
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2025 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version